ROMO1 Antibody (OTI2C12)

Western Blot: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Western Blot: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of extracts (10ug) from 7 different cell lines.

Immunocytochemistry/ Immunofluorescence: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunocytochemistry/Immunofluorescence: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of COS7 cells transiently transfected by pCMV6-ENTRY ROMO1.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Adenocarcinoma of Human ovary tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Human breast tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Human prostate tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Adenocarcinoma of Human colon tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Human pancreas tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Adenocarcinoma of Human endometrium tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Human Kidney tissue.

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607]

Immunohistochemistry: ROMO1 Antibody (OTI2C12) [NBP2-45607] - Analysis of Carcinoma of Human thyroid tissue.

Western Blot: ROMO1 Antibody (OTI2C12) [NBP2-45607] -

The high expression of Romo1 is associated with the poor prognosis of glioblastoma patients. (A) The mRNA levels of Romo1 in the tumor tissues of glioblastoma patients (n=156) and the healthy brain tissues (n=5) were compared. The mRNA levels were compared between the samples with RNA-Seq data published in TCGA database. (B) The survival curves of the glioblastoma patients with high expression (n=127) and low expression (n=384) of Romo1. The mRNA levels were compared between the samples with mRNA microarray data published in TCGA database. (C) The protein levels of Romo1 in different types of patient-derived immune cells were detected by western blotting. (D) The mRNA levels of Romo1 in different types of patient-derived immune cells were analyzed by RT-qPCR. (E) The tissue sections of the paratumors and tumors from glioblastoma patients were analyzed by immunofluorescence with DAPI, Romo1 and CD11b antibodies. The CD11b positive cells and the Romo1 positive cells were quantified and statistically analyzed from three independent experiments. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31945745), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: ROMO1 Antibody (OTI2C12) [NBP2-45607] -

The overexpression of Romo1 in bone marrow cells dampened the immune response in glioblastoma. (A) The overexpression of Romo1 in the bone marrow cells transfected with Romo1-lentivirus (the right lane) was validated by western blotting. The protein sample of the bone marrow cells transfected with control lentivirus (the left lane) was used as control. (B, C) The tumor growth curve (B) and the survival curve (C) of the mice receiving the control bone marrow allografts alone (n=6) or in combination of clodronate liposomes (200ul of each mouse every 3 days, n=6),, and the mice receiving the Romo1-overexpressed bone marrow allografts alone (n=6) in combination of in combination of clodronate liposomes (200ul of each mouse every 3 days, n=6) after orthotopic injection of GL261 cells. (D) The tumor sections were analyzed by immunohistochemistry with CD3 antibody, and the infiltrating CD3+ T cells around tumors were quantified and statistically analyzed. Arrows indicate CD3+ T cells. (E) The frequencies of IFN-gamma -producing CD4+ or CD8+ T cells in tumors of both groups were determined by flow cytometry and statistically analyzed. (F) The frequencies of GzmB-producing CD4+ or CD8+ T cells in tumors of both groups were determined by flow cytometry and statistically analyzed. (G) The tumor sections from both groups were analyzed by immunohistochemistry with Ki-67 antibody and statistically analyzed from three independent experiments. Arrows indicate the Ki-67+ cells. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31945745), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: ROMO1 Antibody (OTI2C12) [NBP2-45607] -

The overexpression of Romo1 promoted macrophage polarization toward M2 phenotype. (A) The control and Romo1-overexpressed macrophages were analyzed by immunofluorescence with CD206 and iNOS antibodies. The CD206+ and iNOS+ cells were quantified and statistically analyzed. (B, C) The control and Romo1-overexpressed macrophages were analyzed by flow cytometry with M1 markers (CD11c and F4/80) and M2 markers (CD206 and CD11b). The double positive cells were respectively quantified and statistically analyzed. (D) The mRNA levels of M1-related genes (IL-6, iNOS, TNF-alpha ) and M2-related genes (Arginase 1, Ym1, IL-10) were determined by RT-qPCR in control and Romo1-overexpressed macrophages. (E) The production of IL-1 beta, IL-12, TGF-beta or IL-23 was respectively analyzed by ELISA in control and Romo1-overexpressed macrophages. Data are representative of at least three independent experiments and are presented as mean +/- SD. ns, not significant; *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/31945745), licensed under a CC-BY license. Not internally tested by Novus Biologicals.